Pear Therapeutics, Inc

Pear Therapeutics, Inc. (PEAR), is a fully integrated digital therapeutics company developing software-based interventions in compliance with FDA design and test requirements, testing the efficacy of these interventions in randomized clinical trials, leveraging clinical trial data to file for FDA approval to treat disease, and supporting payment of approved products via reimbursement codes and health economic analyses. The company has developed a pipeline of clinically validated digital therapies they call eFormulations, and their lead program is on pace to be the first FDA-approved digital therapy, with commercial launch in 2017.